SAN DIEGO, July 13, 2015 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the appointment of Robert E. Hoffman as Chief Financial Officer. Mr. Hoffman joins the company after serving as Chief Financial Officer of Arena Pharmaceuticals, Inc. and Polaris Group.
"I am thrilled to welcome Robert to AnaptysBio and have him join our senior management team," said Hamza Suria, President & CEO of AnaptysBio. "Robert brings tremendous strategic and operational insight in biotech finance to AnaptysBio. He will play a key leadership role as we advance our wholly-owned therapeutic antibody pipeline to key clinical inflection points, including our first-in-class anti-IL-33 and anti-IL-36 receptor antibody programs. We look forward to working closely with Robert to finance AnaptysBio's growth."
"I am pleased to have joined the AnaptysBio team at a very exciting time in the company's evolution," said Robert Hoffman. "AnaptysBio is uniquely positioned with its promising internal pipeline, multiple strategic partnerships, validated antibody technology platform and strong management team. I am attracted to AnaptysBio's strategic focus on driving multiple first-in-class antibodies to clinical POC, while continuing to leverage our technology platform to generate new pipeline assets against emerging disease targets."
Prior to joining AnaptysBio, Mr. Hoffman was employed by Arena Pharmaceuticals, Inc. where since 1997 he served various roles with increasing responsibility leading to Senior Vice President, Finance and Chief Financial Officer since June 2012. From March 2011 to August 2011, Mr. Hoffman served as Chief Financial Officer for Polaris Group. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc. and Kura Oncology, Inc. He also serves as a member of the Financial Accounting Standards Board's Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. In addition, Mr. Hoffman is a member and a former director and President of the San Diego Chapter of Financial Executives International. Mr. Hoffman holds a B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.
AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company's first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO. For more information, visit www.anaptysbio.com.